NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Feb 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
17
Data completeness
5/8 — Partial
Priority Review
AURLUMYN (iloprost) by Johnson & Johnson is 2 . First approved in 2024.
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AURLUMYN (iloprost) is an intravenous prostacycline analog approved by the FDA in February 2024 for vasodilation and platelet aggregation inhibition. It is delivered as an IV solution and represents a new chemical entity in the prostacycline therapeutic class. The drug is indicated for patients requiring acute hemodynamic support and antiplatelet effects.
Growth17.8 years to LOE
Early-stage growth product with 17.8 years of patent protection suggests sustained commercial investment and potential team expansion over the medium term.
Mechanism of Action
2 . Iloprost is a vasodilator and inhibits platelet aggregation.
Pharmacologic Class:
Prostacycline
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (17)
Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in Patients With Septic Shock Suffering From Organ Failure
Started Oct 2019
279 enrolled
Septic Shock
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)
Started Oct 2019
198 enrolled
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)
Started Mar 2019
34 enrolled
Raynaud Phenomenon Secondary to Systemic Sclerosis
Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension
Started Feb 2018
31 enrolled
Hypertension, Pulmonary
Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)
Started Sep 2016
64 enrolled
Hypertension, Pulmonary
Worked on AURLUMYN at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.